Evidence Gaps Analysis
3688 outcomes from 214 review series
CD006205
Current Version: CD006205.PUB5
| 3 older versions
Current Evidence Gaps 38 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| adults with oral cancer | elective radical ND | elective selective ND | Adverse events associated with treatment | Low | Not specified |
| adults with oral or oropharyngeal cancer | sentinel node biopsy | elective ND | Total mortality | Low | Not specified |
| adults with oral or oropharyngeal cancer | sentinel node biopsy | elective ND | New disease, progression, and mortality | Low | Not specified |
| adults with oral or oropharyngeal cancer | sentinel node biopsy | elective ND | Locoregional recurrence | Low | Not specified |
| adults with oropharyngeal cancer | surgery | radiotherapy alone | Total mortality | Low | Not specified |
| adults with oropharyngeal cancer | surgery | radiotherapy alone | New disease, progression, and mortality | Low | Not specified |
| adults with oral cancer | elective ND | therapeutic (delayed) ND | Adverse events associated with treatment | Moderate | Not specified |
| adults with oral cancer | elective ND | therapeutic (delayed) ND | Locoregional recurrence | Moderate | Not specified |
| adults with oral cancer | elective ND | therapeutic (delayed) ND | New disease, progression, and mortality | Moderate | Not specified |
| adults with oral cancer | elective ND | therapeutic (delayed) ND | Mortality | Moderate | Not specified |
| adults with oral cancer | elective ND | therapeutic (delayed) ND | Recurrence | Moderate | Not specified |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned ND before or after chemoradiotherapy | Locoregional recurrence | Moderate | Not specified |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned ND before or after chemoradiotherapy | Total mortality | Moderate | Not specified |
| adults with oral cancer | elective radical ND | elective selective ND | Locoregional recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned ND before or after chemoradiotherapy | Recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned ND before or after chemoradiotherapy | New disease, progression, and mortality | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | superselective ND | selective ND | Recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | superselective ND | selective ND | Total mortality | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | supraomohyoid ND | modified radical ND | Recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | supraomohyoid ND | modified radical ND | Locoregional recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | supraomohyoid ND | modified radical ND | New disease, progression, and mortality | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | supraomohyoid ND | modified radical ND | Total mortality | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | New disease, progression, and mortality | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Adverse events associated with treatment | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | surgery + radiotherapy | radiotherapy alone | New disease, progression, and mortality | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | surgery + radiotherapy | radiotherapy alone | Locoregional recurrence | No Evidence Yet | N/A |
| adults with oral or oropharyngeal cancer | surgery + radiotherapy | radiotherapy alone | Recurrence | No Evidence Yet | N/A |
| adults with oropharyngeal cancer | surgery | radiotherapy alone | Locoregional recurrence | No Evidence Yet | N/A |
| adults with oropharyngeal cancer | surgery | radiotherapy alone | Recurrence | No Evidence Yet | N/A |
| adults with oral cancer | elective radical ND | elective selective ND | New disease, progression, and mortality | Very Low | Not specified |
| adults with oral cancer | elective radical ND | elective selective ND | Total mortality | Very Low | Not specified |
| adults with oral cancer | elective radical ND | elective selective ND | Recurrence | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned ND before or after chemoradiotherapy | Adverse events associated with treatment | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | sentinel node biopsy | elective ND | Adverse events associated with treatment | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | sentinel node biopsy | elective ND | Recurrence | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | superselective ND | selective ND | Locoregional recurrence | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | superselective ND | selective ND | New disease, progression, and mortality | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | superselective ND | selective ND | Adverse events associated with treatment | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | supraomohyoid ND | modified radical ND | Adverse events associated with treatment | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Locoregional recurrence | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Total mortality | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | surgery + radiotherapy | radiotherapy alone | Total mortality | Very Low | Not specified |
| adults with oral or oropharyngeal cancer | surgery + radiotherapy | radiotherapy alone | Adverse events associated with treatment | Very Low | Not specified |
| adults with oropharyngeal cancer | surgery | radiotherapy alone | Adverse events associated with treatment | Very Low | Not specified |
Previous Versions
CD006205.PUB4
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| adults with oral or oropharyngeal cancer | elective neck dissection | therapeutic (delayed) neck dissection | Adverse events | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | elective neck dissection | therapeutic (delayed) neck dissection | Recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | elective radical neck dissection | elective selective neck dissection | Locoregional recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | elective radical neck dissection | elective selective neck dissection | Adverse events | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned neck dissection either before or after chemoradiotherapy | Disease free survival | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned neck dissection either before or after chemoradiotherapy | Adverse events | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned neck dissection either before or after chemoradiotherapy | Recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned neck dissection either before or after chemoradiotherapy | Locoregional recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | super-selective neck dissection | selective neck dissection | Adverse events | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | super-selective neck dissection | selective neck dissection | Locoregional recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | super-selective neck dissection | selective neck dissection | Disease free survival | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | super-selective neck dissection | selective neck dissection | Recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | super-selective neck dissection | selective neck dissection | Total mortality | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | supraomohyoid neck dissection | modified radical neck dissection | Disease free survival | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | supraomohyoid neck dissection | modified radical neck dissection | Total mortality | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | supraomohyoid neck dissection | modified radical neck dissection | Adverse events | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | supraomohyoid neck dissection | modified radical neck dissection | Recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | supraomohyoid neck dissection | modified radical neck dissection | Locoregional recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Total mortality | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Disease free survival | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Locoregional recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Recurrence | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Total mortality | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | surgery + adjuvant radiotherapy | chemotherapy | Adverse events | No Evidence Yet | - |
| adults with oral or oropharyngeal cancer | elective neck dissection | therapeutic (delayed) neck dissection | New disease, progression or mortality | Very Low | - |
| adults with oral or oropharyngeal cancer | elective neck dissection | therapeutic (delayed) neck dissection | Locoregional recurrence | Very Low | - |
| adults with oral or oropharyngeal cancer | elective neck dissection | therapeutic (delayed) neck dissection | Total mortality | Very Low | - |
| adults with oral or oropharyngeal cancer | elective radical neck dissection | elective selective neck dissection | Recurrence | Very Low | - |
| adults with oral or oropharyngeal cancer | elective radical neck dissection | elective selective neck dissection | New disease, progression or mortality | Very Low | - |
| adults with oral or oropharyngeal cancer | elective radical neck dissection | elective selective neck dissection | Total mortality | Very Low | - |
| adults with oral or oropharyngeal cancer | PET-CT following chemoradiotherapy | planned neck dissection either before or after chemoradiotherapy | Total mortality | Very Low | - |
CD006205.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Oral cavity cancer | Radical neck dissection | Selective neck dissection | Disease recurrence | No Evidence Yet | - |
| Oral cavity cancer | Radical neck dissection | Selective neck dissection | Overall survival | No Evidence Yet | - |
| Oral cavity cancer with clinically negative neck nodes | Elective neck dissection | Therapeutic neck dissection | Disease-free survival | No Evidence Yet | - |
| Oral cavity cancer with clinically negative neck nodes | Elective radical neck dissection | Therapeutic neck dissection | Overall survival | No Evidence Yet | - |
| Oral cavity cancer with clinically negative neck nodes | Elective SOH neck dissection | Therapeutic neck dissection | Overall survival | No Evidence Yet | - |
| Oral cavity/oropharyngeal cancer | Surgery plus radiotherapy | Radiotherapy alone | Total mortality | No Evidence Yet | - |
CD006205.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Oral cancer | Surgery + elective supraomohyoid dissection | Surgery alone | Disease-related mortality at 3.5 years | No Evidence Yet | - |
| Oral cancer | Surgery + perioperative MTX | Surgery alone | Recurrent disease at primary site at 1 year | No Evidence Yet | - |
| Oral cancer | Surgery + perioperative MTX | Surgery alone | Total recurrent disease at 1 year | No Evidence Yet | - |
| Oral cancer | Surgery + perioperative MTX | Surgery alone | Disease-free survival at 2 years | No Evidence Yet | - |
| Oral cancer | Surgery + perioperative MTX | Surgery alone | Disease-free survival at 1 year | No Evidence Yet | - |
| Oral/head and neck cancer | Surgery + pre-operative radiotherapy | Surgery alone | Disease-free survival at 1 year | No Evidence Yet | - |
| Oral/head and neck cancer | Surgery + pre-operative radiotherapy | Surgery alone | Disease-related mortality at 1 year | No Evidence Yet | - |
| Oral/head and neck cancer | Surgery + RT + cisplatin | Surgery + RT | Total mortality | No Evidence Yet | - |
| Oral/head and neck cancer | Surgery + RT + cisplatin | Surgery + RT | Death or recurrent disease | No Evidence Yet | - |
| Oral/oropharyngeal cancer | Surgery + conventional PORT | Surgery + accelerated PORT | Death or recurrent disease (neck nodes) | No Evidence Yet | - |
| Oral/oropharyngeal cancer | Surgery + RT + carboplatin/5-FU | Surgery + RT | Death or recurrent disease | No Evidence Yet | - |
| Oral/oropharyngeal cancer | Surgery + RT + IL-2 | Surgery + RT | Recurrent disease at 3 years | No Evidence Yet | - |
| Oral/oropharyngeal cancer | Surgery + RT + IL-2 | Surgery + RT | Disease-free survival at 3 years | No Evidence Yet | - |
CD006334
Current Version: CD006334.PUB4
| 2 older versions
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| nan | Sedation | General anesthesia | nan | No Evidence Yet | N/A |
Previous Versions
CD006334.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| nan | Sedation | General anesthesia | nan | No Evidence Yet | - |
CD006334.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| nan | nan | nan | nan | No Evidence Yet | - |
CD006384
Current Version: CD006384.PUB3
| 1 older version
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| nan | nan | nan | nan | No Evidence Yet | N/A |
Previous Versions
CD006384.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| nan | nan | nan | nan | No Evidence Yet | - |
CD006385
Current Version: CD006385.PUB2
Current Evidence Gaps 6 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| TMJ patients | Arthroscopy | Open surgery | Clinical evaluations at 12 months | No Evidence Yet | N/A |
| TMJ patients | Arthroscopy | Nonsurgical treatment | Pain at 6 months | No Evidence Yet | N/A |
| TMJ patients | Arthroscopy | Arthrocentesis | Pain at 12 months | No Evidence Yet | N/A |
| TMJ patients | Arthroscopy | Arthrocentesis | Maximum interincisal opening at 12 months | No Evidence Yet | N/A |
| TMJ patients | Arthroscopy | Open surgery | Mandibular function at 12 months | No Evidence Yet | N/A |
| TMJ patients | Arthroscopy | Open surgery | Pain at 12 months | No Evidence Yet | N/A |
CD006386
Current Version: CD006386.PUB4
| 2 older versions
Current Evidence Gaps 3 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| people receiving treatment for oral cavity and oropharyngeal cancer | induction chemotherapy plus locoregional treatment | locoregional treatment alone | Overall survival - platinum + 5-FU + surgery vs. surgery | Low | Not specified |
| people receiving treatment for oral cavity and oropharyngeal cancer | induction chemotherapy plus locoregional treatment | locoregional treatment alone | Overall survival - cisplatin + 5-FU + CRT (cisplatin) vs. CRT (cisplatin) | Low | Not specified |
| people receiving treatment for oral cavity and oropharyngeal cancer | induction chemotherapy plus locoregional treatment | locoregional treatment alone | Overall survival - cisplatin + 5-FU + docetaxel + CRT (cisplatin) vs. CRT (cisplatin) | Low | Not specified |
| people receiving treatment for oral cavity and oropharyngeal cancer | concomitant chemoradiotherapy | radiotherapy alone (non-resectable) | Overall survival - CRT vs. RT | Moderate | Not specified |
| people receiving treatment for oral cavity and oropharyngeal cancer | induction chemotherapy plus locoregional treatment | locoregional treatment alone | Overall survival - platinum + 5-FU + RT vs. RT | Moderate | Not specified |
| people receiving treatment for oral cavity and oropharyngeal cancer | surgery + adjuvant treatment A | surgery +/- adjuvant treatment B | Overall survival - adjuvant chemotherapy vs. observation alone | Moderate | Not specified |
| people receiving treatment for oral cavity and oropharyngeal cancer | surgery + adjuvant treatment A | surgery +/- adjuvant treatment B | Overall survival - adjuvant CRT vs. adjuvant RT | Moderate | Not specified |
Previous Versions
CD006386.PUB3
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| patients with oral cavity and oropharyngeal cancer | concomitant chemoradiotherapy | radiotherapy alone | Total Mortality | Low | - |
| patients with oral cavity and oropharyngeal cancer | surgery +/- RT + chemotherapy | surgery +/- RT alone | Total Mortality | Low | - |
| patients with oral cavity and oropharyngeal cancer | concomitant chemoradiotherapy | radiotherapy alone | Total Mortality | Moderate | - |
| patients with oral cavity and oropharyngeal cancer | induction chemotherapy plus locoregional treatment (LRT) | locoregional treatment | Total Mortality | Moderate | - |
| patients with oral cavity and oropharyngeal cancer | surgery +/- RT + chemotherapy | surgery +/- RT alone | Total Mortality | Moderate | - |
| patients with oral cavity and oropharyngeal cancer | induction chemotherapy plus locoregional treatment (LRT) | locoregional treatment | Total Mortality | Very Low | - |
CD006386.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Head and neck cancer patients (>50% oral/oropharyngeal) | Induction chemotherapy + LRT | LRT alone | Total mortality | No Evidence Yet | - |
| Head and neck cancer patients (>50% oral/oropharyngeal) | Induction chemotherapy + LRT | LRT alone | Progression free survival | No Evidence Yet | - |
| Head and neck cancer patients (>50% oral/oropharyngeal) | Induction chemotherapy + LRT | LRT alone | Disease free survival | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Alternating chemoradiotherapy | Radiotherapy alone | Total mortality | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Concomitant chemoradiotherapy | Radiotherapy alone | Progression free survival | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Concomitant chemoradiotherapy | Radiotherapy alone | Locoregional control | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Concomitant chemoradiotherapy | Radiotherapy alone | Disease free survival | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Concomitant chemoradiotherapy | Radiotherapy alone | Total mortality | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Platin + 5-FU concomitant chemoradiotherapy | Radiotherapy alone | Total mortality | No Evidence Yet | - |
| Head and neck cancer patients (non-resectable) | Platin-based concomitant chemoradiotherapy | Radiotherapy alone | Total mortality | No Evidence Yet | - |
| Head and neck cancer patients (post-surgery) | Concomitant chemoradiotherapy | Radiotherapy alone | Disease free survival | No Evidence Yet | - |
| Head and neck cancer patients (post-surgery) | Concomitant chemoradiotherapy | Radiotherapy alone | Total mortality | No Evidence Yet | - |
CD006387
Current Version: CD006387.PUB2
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| people with oral cavity and oropharyngeal cancer | altered fractionation | conventional radiotherapy | Mortality (follow-up: 5 years) | Moderate | Not specified |
| people with oral cavity and oropharyngeal cancer | altered fractionation | conventional radiotherapy | Mortality (follow-up: 5 years) | Very Low | Not specified |
CD006487
Current Version: CD006487.PUB2
Current Evidence Gaps 53 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Low | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Low | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Low | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Low | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Low | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Low | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Moderate | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: pain on injection (solution deposition) | Moderate | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: pain following injection | Moderate | Not specified |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% lidocaine, 1:100,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 2% mepivacaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 3% prilocaine, 0.03 IU felypressin | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:100,000 epinephrine | 2% lidocaine, 1:100,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 0.5% bupivacaine, 1:200,000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Speed of onset of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Adverse effects: allergy to local anaesthetic | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Adverse effects: paraesthesia following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Adverse effects: pain following injection | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Adverse effects: pain on injection (solution deposition) | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% prilocaine plain | 2% lidocaine 1:100, 000 epinephrine | Duration of anaesthesia | No Evidence Yet | N/A |
| Participants regardless of age and gender who were undergoing dental procedures and volunteers who took part in simulated scenario studies in which dental local anaesthesia was tested | 4% articaine, 1:200,000 epinephrine | 4% articaine, 1:100,000 epinephrine | Success of local anaesthesia, measured by the absence of pain during a procedure using a visual analogue scale or other appropriate method (clinical testing of diseased pulps with irreversible pulpitis) | Very Low | Not specified |
CD006538
Current Version: CD006538.PUB2
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| nan | nan | nan | nan | No Evidence Yet | N/A |
CD006540
Current Version: CD006540.PUB2
Current Evidence Gaps 7 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Adults consuming alcohol | Motivational interviewing | Usual care | Drinking >21 units alcohol/week at 12 months | No Evidence Yet | N/A |
| Adults consuming alcohol | Motivational interviewing | Usual care | Drinking >21 units alcohol/week at 3 months | No Evidence Yet | N/A |
| Adults with S. mutans | Sugar restriction advice | No advice | Sugar intake frequency at 12 weeks | No Evidence Yet | N/A |
| Adults with S. mutans | Sugar restriction advice | No advice | Sugar intake frequency at 6 weeks | No Evidence Yet | N/A |
| Children aged 11-12 years | Individualized prevention program | Basic prevention | Using xylitol >3x/day | No Evidence Yet | N/A |
| Edentulous adults | Dietary counseling | Usual care | Starting to drink fruit juice | No Evidence Yet | N/A |
| Edentulous adults | Dietary counseling | Usual care | Fruit consumption (g/day) | No Evidence Yet | N/A |
CD006541
Current Version: CD006541.PUB2
Current Evidence Gaps 1 gap
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Patients with TMD | Orthodontic treatment | No orthodontic treatment | nan | No Evidence Yet | N/A |
CD006542
Current Version: CD006542.PUB3
| 1 older version
Current Evidence Gaps 11 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| People with avulsed and replanted permanent teeth | Extra-oral pulp extirpation at day 0 | Intra-oral extirpation at day 7 | Radiographic resorption (a proxy measure for periodontal healing) at 12 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Hyperbaric oxygen | Control | Pulpal healing at 12 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Hyperbaric oxygen | Control | Tooth survival at 12 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Hyperbaric oxygen | Control | Periodontal healing at 12 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Ledermix | Ultracal | Discolouration at 12 months - patient level - worst case scenario for Ledermix | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Ledermix | Ultracal | Periodontal healing at 12 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Ledermix | Ultracal | Tooth survival at 12 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Ledermix | Ultracal | Discolouration at 12 months - patient level - best case scenario for Ledermix | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Thymosin alpha 1 | Control (saline) | Periodontal healing at 48 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Thymosin alpha 1 | Control (saline) | Tooth survival at 48 months | Very Low | Not specified |
| People with avulsed and replanted permanent teeth | Thymosin alpha 1 | Control (saline) | Tooth survival at 12 months | Very Low | Not specified |
Previous Versions
CD006542.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with avulsed teeth | Extra-oral pulp extirpation at day 0 | Intra-oral pulp extirpation at week 1 | Root resorption at 12 months | No Evidence Yet | - |
| Patients with avulsed teeth | Hyperbaric oxygen | Control | Pulp survival at 12 months (worst case) | No Evidence Yet | - |
| Patients with avulsed teeth | Hyperbaric oxygen | Control | Tooth survival at 12 months (worst case) | No Evidence Yet | - |
| Patients with avulsed teeth | Hyperbaric oxygen | Control | Periodontal healing at 12 months (worst case) | No Evidence Yet | - |
| Patients with avulsed teeth | Hyperbaric oxygen | Control | Pulp survival at 12 months | No Evidence Yet | - |
| Patients with avulsed teeth | Hyperbaric oxygen | Control | Tooth survival at 12 months | No Evidence Yet | - |
| Patients with avulsed teeth | Hyperbaric oxygen | Control | Periodontal healing at 12 months | No Evidence Yet | - |
| Patients with avulsed teeth | Thymosin alpha 1 soaking | Saline soaking | Periodontal healing at 48 months (worst case) | No Evidence Yet | - |
| Patients with avulsed teeth | Thymosin alpha 1 soaking | Saline soaking | Periodontal healing at 48 months | No Evidence Yet | - |
| Patients with avulsed teeth | Thymosin alpha 1 soaking | Saline soaking | Tooth survival at 48 months (worst case) | No Evidence Yet | - |
| Patients with avulsed teeth | Thymosin alpha 1 soaking | Saline soaking | Tooth survival at 48 months | No Evidence Yet | - |
CD006697
Current Version: CD006697.PUB2
| 1 older version
Current Evidence Gaps 10 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Edentulous mandibles | Crestal incision | Vestibular incision | Prosthesis/implant failure | No Evidence Yet | N/A |
| Fully edentulous maxillae | Flapless surgery | Flap elevation | Implant failure | No Evidence Yet | N/A |
| Implant patients | Erbium:YAG laser | Conventional flap | Postoperative pain | No Evidence Yet | N/A |
| Implants with minimal keratinized mucosa | Xenogeneic collagen matrix | Connective tissue autograft | Recession | No Evidence Yet | N/A |
| Implants with minimal keratinized mucosa | Xenogeneic collagen matrix | Connective tissue autograft | Keratinized mucosa width | No Evidence Yet | N/A |
| Partially edentulous patients | Flapless surgery | Flap elevation | Prosthesis/implant failure | No Evidence Yet | N/A |
| Partially edentulous patients | Flapless surgery | Flap elevation | Patient preference | No Evidence Yet | N/A |
| Partially edentulous patients | Flapless surgery | Flap elevation | Postoperative pain | No Evidence Yet | N/A |
| Posterior mandible | Connective tissue graft | No augmentation | Pink aesthetic scores | No Evidence Yet | N/A |
| Posterior mandible | Connective tissue graft | No augmentation | Soft tissue thickness | No Evidence Yet | N/A |
Previous Versions
CD006697
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Dental implant patients | Erbium:YAG laser | Conventional flap elevation | Postoperative pain | No Evidence Yet | - |
| Partially edentulous patients | Flapless surgery | Conventional flap elevation | Complications | No Evidence Yet | - |
| Partially/fully edentulous patients | Crestal incision | Vestibular incision | Postoperative complications | No Evidence Yet | - |
| Partially/fully edentulous patients | Flapless surgery | Conventional flap elevation | Postoperative pain | No Evidence Yet | - |
CD006698
Current Version: CD006698.PUB2
| 1 older version
Current Evidence Gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| patients requiring dental implants | 1-stage placement | 2-stage placement | Implant failure | Moderate | Not specified |
| patients requiring dental implants | 1-stage placement | 2-stage placement | Prosthetic failure | Moderate | Not specified |
Previous Versions
CD006698
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Adults requiring mandibular implants | 1-stage implant procedure | 2-stage implant procedure | Prosthesis failure | No Evidence Yet | - |
| Adults requiring mandibular implants | 1-stage implant procedure | 2-stage implant procedure | Implant failure | No Evidence Yet | - |
CD006700
Current Version: CD006700.PUB2
Current Evidence Gaps 9 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of drooling (days) | No Evidence Yet | N/A |
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of viral shedding (days) | No Evidence Yet | N/A |
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of drinking difficulties (days) | No Evidence Yet | N/A |
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of eating difficulties (days) | No Evidence Yet | N/A |
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of extraoral lesions (days) | No Evidence Yet | N/A |
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of fever (days) | No Evidence Yet | N/A |
| Children 1-6 years with gingivostomatitis | Acyclovir | Placebo | Duration of oral lesions (days) | No Evidence Yet | N/A |
| Children mean age 2 years with herpetic infection | Acyclovir tablets | Placebo | Time to resolution of pain | No Evidence Yet | N/A |
| Children mean age 2 years with herpetic infection | Acyclovir tablets | Placebo | Time to resolution of hypersialorrhea | No Evidence Yet | N/A |
CD006701
Current Version: CD006701.PUB2
Current Evidence Gaps 5 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Adults with halitosis | Cetylpyridinium chloride + essential oils + chlorine dioxide + zinc (Breath Rx) | Placebo | VSC reduction at 4 weeks | No Evidence Yet | N/A |
| Adults with halitosis | Chlorhexidine + cetylpyridinium chloride + zinc lactate | Placebo | VSC reduction at 2 weeks | No Evidence Yet | N/A |
| Adults with halitosis | Chlorhexidine + cetylpyridinium chloride + zinc lactate | Placebo | Organoleptic score reduction at 2 weeks | No Evidence Yet | N/A |
| Adults with halitosis | Garcinia mangostana L extract | Placebo | VSC reduction at 15 days | No Evidence Yet | N/A |
| Adults with halitosis | Two-phase oil-water (0.05% cetylpyridinium chloride) | Essential oils (Listerine) | Organoleptic score reduction at 6 weeks | No Evidence Yet | N/A |
CD006703
Current Version: CD006703.PUB2
Current Evidence Gaps 8 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Pre-operative gap size during speech (Group 2) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Post-operative gap size during closure (Group 2) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Post-operative gap size during closure (Group 1) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Complete closure (Group 2) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Complete closure (Group 1) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Residual post-operative VPI (Group 2) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Residual post-operative VPI (Group 1) | No Evidence Yet | N/A |
| Children aged 4-7 years with submucous cleft palate | MIPP | MIPP with additional velopharyngeal surgery | Pre-operative gap size during speech (Group 1) | No Evidence Yet | N/A |
CD006706
Current Version: CD006706.PUB2
Current Evidence Gaps 12 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Cancer patients | Aciclovir | Placebo | Viral isolates | No Evidence Yet | N/A |
| Cancer patients | Aciclovir | Placebo | HSV oral lesions | No Evidence Yet | N/A |
| Cancer patients | IV aciclovir | Placebo | Viral isolates | No Evidence Yet | N/A |
| Cancer patients | IV aciclovir | Placebo | HSV oral lesions | No Evidence Yet | N/A |
| Cancer patients | Oral aciclovir | Placebo | HSV oral lesions | No Evidence Yet | N/A |
| Cancer patients | Oral aciclovir | Oral valaciclovir | HSV lesions | No Evidence Yet | N/A |
| Cancer patients | Oral aciclovir | Placebo | Viral isolates | No Evidence Yet | N/A |
| Cancer patients | Prostaglandin E | Placebo | Viral isolates | No Evidence Yet | N/A |
| Cancer patients (adults+children) | Aciclovir | Placebo | HSV oral lesions | No Evidence Yet | N/A |
| Cancer patients (adults+children) | Aciclovir | Placebo | Viral isolates | No Evidence Yet | N/A |
| Cancer patients (adults only) | Aciclovir | Placebo | Viral isolates | No Evidence Yet | N/A |
| Cancer patients (adults only) | Aciclovir | Placebo | HSV oral lesions | No Evidence Yet | N/A |
CD006963
Current Version: CD006963.PUB2
Current Evidence Gaps 6 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Patients with mandibular prognathism | IVRO | SSRO | Sagittal changes of pogonion (1 week to 1 year) | No Evidence Yet | N/A |
| Patients with mandibular prognathism | IVRO | SSRO | Vertical changes of pogonion (1 week to 1 year) | No Evidence Yet | N/A |
| Patients with mandibular prognathism | IVRO | SSRO | Vertical changes of B-point (1 week to 1 year) | No Evidence Yet | N/A |
| Patients with mandibular prognathism | IVRO | SSRO | Sagittal changes of B-point (1 week to 1 year) | No Evidence Yet | N/A |
| Patients with mandibular prognathism | VRO with osteosynthesis | VRO without osteosynthesis | Fossa-condyle relations anterior (1 year) | No Evidence Yet | N/A |
| Patients with mandibular prognathism | VRO with osteosynthesis | VRO without osteosynthesis | Fossa-condyle relations posterior (1 year) | No Evidence Yet | N/A |
CD006966
Current Version: CD006966.PUB3
| 1 older version
Current Evidence Gaps 6 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| People with maxillary palatally impacted canines | Open surgical technique | Closed surgical technique | Gum health | Low | Not specified |
| People with maxillary palatally impacted canines | Open surgical technique | Closed surgical technique | Success of surgery | Low | Not specified |
| People with maxillary palatally impacted canines | Open surgical technique | Closed surgical technique | Complications | No Evidence Yet | N/A |
| People with maxillary palatally impacted canines | Open surgical technique | Closed surgical technique | Patient response | Very Low | Not specified |
| People with maxillary palatally impacted canines | Open surgical technique | Closed surgical technique | Aesthetics | Very Low | Not specified |
| People with maxillary palatally impacted canines | Open surgical technique | Closed surgical technique | Treatment time | Very Low | Not specified |
Previous Versions
CD006966.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| nan | nan | nan | nan | No Evidence Yet | - |
CD006968
Current Version: CD006968.PUB3
| 1 older version
Current Evidence Gaps 12 gaps
| Population | Intervention | Comparison | Outcome | Evidence Level | Downgrade Reason |
|---|---|---|---|---|---|
| Patients having a tooth extraction | Chlorhexidine gel | Chlorhexidine rinse | Presence of dry socket | Low | Not specified |
| Patients having a tooth extraction | Chlorhexidine gel | Placebo/no treatment | Presence of dry socket | Moderate | Not specified |
| Patients having a tooth extraction | Chlorhexidine rinse | Placebo/no treatment | Presence of dry socket | Moderate | Not specified |
| Adults with dry socket | Zinc oxide eugenol | Alvogyl | Swelling | No Evidence Yet | N/A |
| Adults with dry socket | Zinc oxide eugenol | Alvogyl | Adverse effects | No Evidence Yet | N/A |
| Adults with dry socket | Zinc oxide eugenol | Alvogyl | Healing | No Evidence Yet | N/A |
| Adults with dry socket | Zinc oxide eugenol | Alvogyl | Fever | No Evidence Yet | N/A |
| Adults with dry socket | Zinc oxide eugenol | Alvogyl | Limitation of chewing or swallowing | No Evidence Yet | N/A |
| Patients having a tooth extraction | Chlorhexidine gel | Chlorhexidine rinse | Adverse events | No Evidence Yet | N/A |
| Patients having a tooth extraction | Chlorhexidine gel | Placebo/no treatment | Adverse events | No Evidence Yet | N/A |
| Patients having a tooth extraction | Chlorhexidine rinse | Placebo/no treatment | Adverse events | No Evidence Yet | N/A |
| Patients having a tooth extraction | Platelet rich plasma | Placebo/no treatment | Adverse events | No Evidence Yet | N/A |
| Adults with dry socket | Zinc oxide eugenol | Alvogyl | Pain | Very Low | Not specified |
| Patients having a tooth extraction | Platelet rich plasma | Placebo/no treatment | Presence of dry socket | Very Low | Not specified |
Previous Versions
CD006968.PUB2
| Population | Intervention | Comparison | Outcome | Evidence Level | Studies |
|---|---|---|---|---|---|
| Patients with the management of dry socket | Chlorhexidine gel | Control | Presence of dry socket | Moderate | - |
| Patients with the management of dry socket | Chlorhexidine rinse | Control | Presence of dry socket | Moderate | - |
Showing 101 to 120 of 214 review series
Summary Statistics
214
Review Series
3688
PICO Questions
Evidence Certainty
High
(%)
Moderate
(%)
Low
(%)
Very Low
(%)
No Evidence Yet
(%)
GRADE Downgrading Reasons
Risk of Bias
985
(85.8%)
Imprecision
895
(78.0%)
Inconsistency
253
(22.0%)
Indirectness
188
(16.4%)
Publication Bias
48
(4.2%)